Article
Oncology
Mohammed S. I. Mansour, Tomas Seidal, Ulrich Mager, Katalin Dobra, Hans Brunnstrom, Annika Dejmek
Summary: This study found a moderate concordance of PD-L1 expression between biopsies and effusions from pleural malignant mesothelioma (MM) patients, especially in the epithelioid MM subtype. PD-L1 positivity in biopsies correlated with the histologic subtype, but not in effusions.
CANCER CYTOPATHOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Mohammed S. Mansour, Karina Malmros, Ulrich Mager, Kajsa Ericson Lindquist, Kim Hejny, Benjamin Holmgren, Tomas Seidal, Annika Dejmek, Katalin Dobra, Maria Planck, Hans Brunnstrom
Summary: This study aimed to explore the potential impacts of various clinicopathological and molecular factors on PD-L1 expression. The results showed that tumor histology and mutational status were correlated with PD-L1 expression. These findings are important for further understanding the treatment response in this disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Anatomy & Morphology
Birgit G. Skov
Summary: Concordance between the three validated commercial PD-L1 assays and their associated platforms has been demonstrated in non-small cell lung cancer. The difficulty of scoring PD-L1 expression mainly lies in samples with Tumor Proportion Scores between 1% to 49%. High agreement was found between PD-L1 IHC 22C3 pharmDx on different platforms, with no difference in scoring difficulty between them.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
(2021)
Article
Pathology
Francesca Ambrosi, Francesca Giunchi, Elisa Capizzi, Alessandra Cancellieri, Rocco Trisolini, Andrea Ardizzoni, Michelangelo Fiorentino, Costantino Ricci
Summary: This study evaluated the cyto-histological agreement and the PD-L1 interobserver agreement among three different pathologists on paired cytological smears and histological samples of advanced NSCLC. The results showed good agreement in CHA for some pathologists and moderate agreement in IrOA for smears. However, good agreement was observed for histological samples. Therefore, PD-L1 assessment on cytological smears should be improved and could be an alternative for patients without FFPE samples.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Article
Oncology
Sally C. M. Lau, Madhumitha Rabindranath, Jessica Weiss, Janice J. N. Li, Andrea S. Fung, Dorinda Mullen, Najd Alshamlan, Heather M. Ruff, Leung Chu B. Tong, Prodipto Pal, Michael R. Cabanero, Ying-Han R. Hsu, Adrian G. Sacher, Frances A. Shepherd, Geoffrey Liu, Penelope A. Bradbury, Kazuhiro Yasufuku, Katarzyna Czarnecka-Kujawa, Hyang Mi Ko, Ming-Sound Tsao, Natasha B. Leighl, Joerg Schwock
Summary: Treatment outcomes based on PD-L1 scores derived from both cytology and histology specimens showed similar results in patients receiving single agent immune checkpoint inhibitor therapy. This study suggests that PD-L1 biomarker testing can be applied to both cytology and histology specimens.
Article
Oncology
Denis Leonardo Jardim, Karthikeyan Murugesan, Julia A. Elvin, Richard S. P. Huang, Razelle Kurzrock
Summary: PD-L1 (CD274) amplification level and focality have an impact on PD-L1 protein expression. PD-L1 amplification was detected using a comparative genomic hybridization-like method and PD-L1 protein expression was analyzed by immunohistochemistry (IHC) using the DAKO 22C3 antibody. A total of 60,793 samples were analyzed, with the most common histologies being lung adenocarcinoma (20%), colon adenocarcinoma (12%), and lung squamous carcinoma (8%). The study found that 1.21% of tumors (738/60,793) had PD-L1 amplification. Focality categories ranged from <0.1 mB (2.4%) to >= 20 mB (24.4%). Lower levels of PD-L1 amplification were more frequently non-focal, while more focal amplifications correlated with higher PD-L1 IHC expression. The median tumor proportion score (TPS) for PD-L1 amplified samples according to focality ranged from 87.5% (<0.1 mB) to 1% (>= 20mB). In conclusion, PD-L1 protein expression is influenced by the level and focality of PD-L1 amplification.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Pathology
Anne Grabenstetter, Achim A. Jungbluth, Denise Frosina, Raza Hoda, Carlos H. Dos Anjos, Sujata Patil, Varadan Sevilimedu, Britta Weigelt, Jorge S. Reis-Filho, Hong Zhang, Tiffany Traina, Mark E. Robson, Edi Brogi, Hannah Y. Wen
Summary: Immunotherapy targeting PD-L1/programmed death-1 may benefit patients with MpBC, with most cases showing PD-L1 positivity in immune cells. However, there is variability in PD-L1 expression rates depending on the assay used. The SP142 assay demonstrates distinct expression patterns compared to E1L3n and 73-10, highlighting the importance of considering assay-specific characteristics in interpreting PD-L1 expression.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2021)
Article
Pathology
Seshi R. Sompuram, Emina E. Torlakovic, Nils A. 't Hart, Kodela Vani, Steven A. Bogen
Summary: Companion diagnostic immunohistochemistry tests have been developed and performed without considering laboratory metrology principles. This study introduced new IHC calibrators traceable to NIST Standard Reference Material, which quantified analytic parameters and revealed differences in sensitivity among FDA-cleared PD-L1 assays. Calibrating PD-L1 tests clarifies performance characteristics, explains discrepancies in test results, and improves patient treatment outcomes and test harmonization.
Article
Oncology
Yen-Yu Lin, Li-Ya Lin, Jen-Fan Hang, Chia-Hung Lin, Hsiang-Ling Ho, Teh-Ying Chou
Summary: The PD-L1/TTF-1 double immunohistochemistry technique can better identify PD-L1-positive tumor cells in cytopathology specimens. In cytopathology specimens, double staining can improve the concordance between visual estimation by pathologists and cell counting by medical technologists.
CANCER CYTOPATHOLOGY
(2021)
Review
Medicine, General & Internal
Giulio Rossi, Fabio Davoli, Venerino Poletti, Alberto Cavazza, Filippo Lococo
Summary: This article highlights the wide spectrum of clinical and radiological presentation of malignant mesothelioma, the possibility of using cytology for continuous diagnosis, and proposes some alternative and more unbiased approaches to diagnosing MPM.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pathology
Sigurd A. Saastad, Anette H. Skjervold, Borgny Ytterhus, Monica Jernberg Engstrom, Anna M. Bofin
Summary: This study assessed the expression of PD-L1 in tumor epithelial cells and tumor-infiltrating immune cells (TICs) and its relationship with prognosis in patients with breast cancer. The results showed that PD-L1 was more frequently expressed in TICs and was associated with aggressive tumor characteristics and molecular subtypes, but not with prognosis.
JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Oncology
Richard S. P. Huang, James Haberberger, Lukas Harries, Eric Severson, Daniel L. Duncan, N. Lynn Ferguson, Amanda Hemmerich, Claire Edgerly, Karthikeyan Murugesan, Jinpeng Xiao, Deborah McEwan, Oliver Holmes, Matthew Hiemenz, Jeffrey Venstrom, Julia A. Elvin, James Creeden, Douglas I. Lin, Jeffrey S. Ross, Shakti H. Ramkissoon
Summary: This study found genomic differences between PD-L1(positive) and PD-L1(negative) urothelial carcinomas, providing a framework for future clinical investigation. Additionally, differences in PD-L1 positivity based on sample collection sites were observed, which could influence sample selection for PD-L1 testing in patients with urothelial carcinoma.
Article
Ophthalmology
Clelia Miracco, Paolo Toti, Maria Chiara Gelmi, Sara Aversa, Gennaro Baldino, Paolo Galluzzi, Sonia De Francesco, Federica Petrelli, Ester Sorrentino, Giuseppe Belmonte, Daniela Galimberti, Sandra Bracco, Theodora Hadjistilianou
Summary: Chemotherapy modulates the tumor microenvironment of retinoblastoma, reorienting it from an anergic state into an active, CD8+, PD-L1+ hot state, thereby enhancing the host's anti-tumor immunity. Additionally, certain clinicopathological characteristics of retinoblastoma correlate with several factors of the tumor microenvironment.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
(2021)
Review
Health Care Sciences & Services
Stefano Marletta, Nicola Fusco, Enrico Munari, Claudio Luchini, Alessia Cimadamore, Matteo Brunelli, Giulia Querzoli, Maurizio Martini, Elena Vigliar, Romano Colombari, Ilaria Girolami, Fabio Pagni, Albino Eccher
Summary: This paper provides an update on the assessment of PD-L1 expression in various types of tumors. While robust data and specific protocols are available for some tumors, further studies and clinical trials are needed to harmonize the topic in other less explored fields.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Alejandro Aviles-Salas, Luis Cabrera-Miranda, Norma Hernandez-Pedro, Diana Sofia Vargas-Lias, Suraj Samtani, Wendy Munoz-Montano, Daniel Motola-Kuba, Luis Corrales-Rodriguez, Claudio Martin, Andres F. Cardona, Cittim B. Palomares-Palomares, Oscar Arrieta
Summary: This study investigated the prognostic value of PD-L1 expression in patients with MPM and found that high PD-L1 expression was associated with worse survival outcomes. Adding PD-L1 to the CALGB scoring system improved the prognostic estimation of MPM survival.
FRONTIERS IN ONCOLOGY
(2023)